viewLexagene Holdings Inc

LexaGene Holdings clarifies terms of offering to raise funds for R&D, marketing

The biotechnology company plans to raise a minimum of C$3.5 million up to a maximum of C$10 million

canadian money
The firm is getting ready to widely launch the LX2 Genetic Analyzer

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) updated shareholders on Wednesday about the terms of its financing to fund further research and development of its genetic analyzer technology.

The company told investors last week that it had filed a preliminary prospectus with the securities regulatory authorities in each of the Canadian provinces, except Quebec, relating to the planned sale of units to raise a minimum of $3.5 million and a maximum of $10 million.  

Massachusetts-based LexaGene said it plans to use the proceeds for research and development, marketing, and possibly to support the building of inventory and initial commercial sales.

READ: LexaGene Holdings files preliminary prospectus relating to offering to raise funds for R&D, marketing

Under the financing's terms, the company will offer a minimum of just over 6.7 million units and a maximum of 19.2 million units priced at C$0.52.

Each unit comprises one share and one warrant exercisable at C$0.75 for a 36-month period following the closing date.

Industrial Alliance Securities Inc will act as lead agent for the offering in Canada. The offering is being undertaken on a commercially reasonable “best efforts” agency basis in each of the provinces of Canada, except Quebec.

LexaGene said that closing of the offering is expected to occur by October 10 subject to regulatory approval.

The firm is getting ready to widely launch the LX2 Genetic Analyzer to the veterinary industry and other underserved markets valued at an estimated US$40 billion.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Lexagene Holdings Inc

Price: 0.5 CAD

Market: TSX-V
Market Cap: $35.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...



Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 17/9/19

2 min read